The Senior Director, Health Economics and Outcomes Research (HEOR) & Pricing will lead Rocket’s integrated pricing, value and evidence framework to support the clinical, economic, societal and access value of Rocket's gene therapy portfolio, with a primary focus on rare genetic cardiomyopathies and one-time in-vivo AAV gene therapies.

• Lead development of integrated economic narrative and value communication platforms that articulate the clinical, economic, societal and health-system value of Rocket therapies for payers, HTA agencies, providers and health systems.
• Build a clear health-economic and access value proposition for Rocket's genetic cardiomyopathy portfolio
• Develop and execute global HEOR strategy and tactics aligned with product strategy and market access priorities, to support optimal access, reimbursement and value recognition for Rocket gene therapies.
• Serve as a strategic bridge across U.S. and ex-U.S. stakeholders to ensure evidence plans reflect evolving payer insights, HTA requirements, regional access considerations and launch sequencing priorities while maintaining a consistent global value framework.

Pricing strategy and access architecture

• Define global pricing architecture and strategy for one-time gene therapies, incorporating launch sequencing, HTA value thresholds, international reference pricing, country access archetypes, market-specific reimbursement pathways, evidence threshold assessment
• Outline novel approaches to shape sustainable access and value recognition for one-time gene therapies. Design and conduct payer and pricing research, advisory boards and value message testing.
• Monitor U.S. and ex-U.S. policy, payer, HTA and reimbursement dynamics that may influence patient access, price realization, affordability, uptake and reimbursement for Rocket's gene therapy portfolio.

Evidence generation, RWE and economic modeling

• Build and execute health economic strategy to support access value proposition, including burden of illness studies, cost-effectiveness models, budget impact models, and scenario analyses that demonstrate value to patients, payers, health systems and society.
• Design and implement real-world evidence programs to strengthen the target product profile, address payer evidence needs and support market access across geographies, including systematic literature reviews, evidence synthesis, natural history and real-world data analyses, registry strategies, and post-launch evidence plans.
• Conduct economic evaluations as the basis for payer assessments, HTA submissions, disease management guidelines and formulary evaluations.
• Translate HEOR evidence into payer-facing tools and resources, including AMCP dossiers, value communication materials, pricing and access support tools, and payer engagement materials.
• Identify and address evidence needs related to genetic testing access, diagnostic pathways, patient identification and payer coverage of testing for genetic cardiomyopathies

Clinical development and access readiness alignment

• Partner closely with Clinical Development, Medical Affairs, Product Strategy and Marketing to establish an integrated value and evidence strategy that aligns evidence generation with payer access expectations consistent with country launch priorities
• Collaborate with Clinical Development to ensure clinical trial designs capture data relevant to payers and HTA bodies and outcomes relevant to value-based access models.
• Define and validate healthcare resource utilization (HCRU), quality of life (QoL), patient-reported outcome (PRO) and caregiver burden endpoints for clinical trials and observational studies across phases of development.
• Support additional indications, life-cycle management and broader gene therapy portfolio strategy through scalable evidence, pricing and access frameworks.

Stakeholder engagement and operating infrastructure

• Engage with the HEOR community, payer advisors, HTA consultants, clinical or academic partners and external experts in medicine, health economics and outcomes research to shape strategies.
• Present access, evidence, HEOR and pricing insights succinctly so executive leadership and internal or external stakeholders can understand the strategic significance of findings, assumptions and recommendations.
• Oversee and optimize the global value and evidence budget, ensuring strategic resource allocation, vendor efficiency, quality standards, timeline discipline and fit-for-purpose deliverables.
• Strengthen global HEOR, pricing and value evidence infrastructure, including evidence-planning processes, model governance, materials approval processes, guidance documents and SOPs.

• Advanced degree required, such as PhD, PharmD, MD, MPH, MSc, MBA or equivalent degree in health economics, outcomes research, epidemiology, public health, pharmacy, medicine, economics, pricing, market access or a related scientific or quantitative discipline.
• 15 years of experience with demonstrated ability to conduct pharmacoeconomic research and analysis, health policy, health program evaluation in the international biopharmaceutical industry
• Publication record or demonstrated experience communicating HEOR, RWE, economic modeling, pricing or value evidence in scientific, payer-facing or executive settings.
• Demonstrated success leading HEOR strategy and execution with a deep understanding of diverse healthcare systems, payer landscapes, HTA processes, reimbursement dynamics and regulatory environments.
• Experience with pricing and access strategy for specialty, rare disease or high-value therapies. Preference for experience with cell and gene therapy, rare cardiovascular disease, or ultra-rare disease areas.
• Experience managing HEOR, pricing, payer research or value evidence vendors internationally, including budgets, timelines, quality standards and cross-functional deliverables.
• Capable of leading cross-functional teams and influencing across Product Strategy, Marketing, Clinical Development, Medical Affairs, Regulatory and external partners.
• Exceptional verbal, written and presentation skills, including the ability to distill complex evidence, pricing logic and access considerations into compelling insights for executive leadership, global stakeholders and external audiences.
• Adept at managing multiple high-impact initiatives simultaneously, exercising sound judgment in prioritizing strategic deliverables in a fast-moving biotechnology environment.
• Collaborative, practical and solution-oriented leadership style with sound judgment, high accountability and the ability to build alignment across teams.